

Integrative Methods for Analysing Big Data in Precision Medicine

Vladimir Gligorijević^{1,†}, Noël Malod-Dognin^{1,†}, and Nataša Pržulj^{1,*}

¹Department of Computing, Imperial College London, SW7 2AZ London, United Kingdom

*natasha@imperial.ac.uk

†both authors contributed equally

ABSTRACT

We provide an overview of recent developments in big data analyses in the context of precision medicine and health informatics. With the advance in technologies capturing molecular and medical data, we entered the area of Big Data in biology and medicine. These data offer many opportunities to advance precision medicine. We outline key challenges in precision medicine and present recent advances in data integration-based methods to uncover personalized information from big data produced by various omics studies. We survey recent integrative methods for disease subtyping, bio-markers discovery and drug repurposing, and list the tools that are available to domain scientists. Given the ever-growing nature of these big data, we highlight key issues that big data integration methods will face.

1 Introduction

Precision medicine, also known as personalized, predictive, preventive and participatory (P4) medicine¹, is an emerging approach for individualizing the practice of medicine². Prevention and treatment strategies that take into account individual variability are not new; for example, blood-typing has been used to guide blood transfusion for more than a century, with a total of 35 human blood groups being recognized by the International Society of Blood Transfusion.³ Similarly, gender, race, time of ischaemia, cytomegalovirus and sero-type are taken into account to reduce the risk of rejecting organ transplantations⁴⁻⁷. The challenge in applying the precision medicine concept to omics and clinical data sets of patient features that have become available and that cannot be interpreted directly by medical practitioners due to their large sizes and complexities.

Big data is a broad term for data sets so large or complex that traditional data processing methods are inadequate. It is often characterized by three Vs⁸: volume, which refers to the large size of the data, velocity, which refers to the high speed at which data are generated, and variety, which refers to the heterogeneity of the data coming from different sources. All these characteristics apply to currently available biological and medical datasets. Since the beginning of the Human Genome Project⁹, novel technological developments led to the era of omics sciences. Using novel high-throughput capturing technologies, we are now able to access the DNA of an individual (genetic data), the transcribed RNA over time (expression and co-expression data), proteins (protein profiles and protein interaction data), metabolism (metabolic profiles) and epigenome (DNA methylation data), among other data types¹⁰. The environment is also taken into account (e.g., nutrition and bacterial environment by nutriomics and metagenomics, respectively)^{11,12}, and also histopathological and medical imaging data are now subject to high throughput capturing and analysis methods¹³⁻¹⁶.

Therefore, we are facing an increasing gap between our ability to generate big biomedical data and our ability to analyse and interpret them¹⁷. In this context, it is not surprising that big data and precision medicine are jointly investigated. In 2011, the “Big Data Research and Development Initiative”¹ was targeting personalized medicine through the GenISIS program (Genomic Information System for Integrated Science) to enhance health care for Veterans. In 2012, the US National Institutes of Health (NIH) launched the “Big Data to Knowledge” initiative, to harvest the wealth of information contained in biomedical Big Data¹⁸. Finally, President Obama recently announced the “Precision Medicine” initiative², with an ambitious goal of driving precision medicine by incorporating many different types of data, from genomes to microbiomes, with patient data collected by health care providers and patients themselves.

Out of many challenges in precision medicine, here we focus on four related problems: patient sub-typing, bio-marker discovery, drug repurposing and personalized treatment prediction. We provide a review of methods capable of integrative analyses of multiple data types in addressing these problems.

¹<https://www.whitehouse.gov/blog/2012/03/29/big-data-big-deal>

²<https://www.whitehouse.gov/precision-medicine>

Sub-typing and Bio-marker discovery. Also known as patient stratification, sub-typing is the task of identifying sub-populations of patients that can be used to guide treatment procedures of a given individual belonging to the sub-population, and to predict the outcomes. Sub-typing identifies *endotypes*, which refer to sub-types in which patients are related by similarities in their underlying disease mechanisms (i.e., to explain the diseases mechanisms)¹⁹, and *verotypes*, which refer to true populations of similar patients for treatment purposes (i.e., to predict therapies for curing the patients)²⁰. However, what precisely constitutes endotypes and verotypes, as well as how they should be discovered, remains open. Despite varying definitions, sub-typing remains a classification task and an active and growing area of machine learning research (see Section 3.1). Diseases such as cancer, autism, autoimmune diseases, cardiovascular diseases and Parkinson's have all been studied through the lens of subtyping²¹⁻²³.

According to FDA, a bio-marker is any measurable diagnostic indicator that is used to assess the risk, or presence of a disease²⁴. Bio-marker discovery aims at finding features that are characteristic to particular patient sub-populations (e.g., specific gene mutations in tumour tissues, specific miRNAs, metabolites, etc.). The goal is that an individual is only tested for bio-markers to decide whether or not she/he belongs to a specific patient sub-type. Bio-markers are considered key to improving health-care and lowering medical costs²⁵.

Drug repurposing and personalised treatment. Drug repurposing refers to the identification and development of new uses for the existing, or abandoned pharmacotherapies. Capitalising on already known drugs allows for reducing the cost of developing pharmacotherapies compared with de novo drug discovery and development²⁶. With the availability of various omics data, computational predictions of new drug candidates for repurposing have necessitated the development of many new methods for data integration (see Section 3.2).

Drug repurposing is not only about identifying new targets for known drugs; preclinical evaluations also include predicting therapeutic regimens (i.e., dose and frequency) and safety of the treatment (i.e., side effects). Bringing together patient sub-typing and precise prediction of therapeutic treatment outcomes is key for deriving personalised treatments. For example, the American Society of Clinical Oncology estimates that testing colon cancer patients for mutations in K-RAS gene would save \$604 million in drug costs annually; since patients with these mutations **do** not respond well to EGF inhibitors, it is preferable to avoid giving them an inefficient and potentially toxic treatment, which is also very expensive (\$100,000 per treatment)³.

In this paper, we give an overview of the available methods for analysing large and diverse biomedical data, introduce concepts of data integration and classification, and elaborate on the successes and limitations of Big Data approaches in precision medicine.

2 Big Data

2.1 Avalanche of Omics data

With the recent advances in biomedical data capturing technologies, omics sciences produce ever increasing amounts of biomedical data. We briefly present key available omics data types, which are illustrated in Figure 1.

Genomics and exomics. Genomics is a part of genetics that focuses on capturing whole genomes. Historically, the Human Genome Project required 12 years and \$3 billion to capture the first human genome, with a final release in 2003 reporting about 20,500 genes⁹. The first commercial next generation sequencer (NGS), the Roche GS-FLX 454 (released in 2004), allowed capturing the second human genome in two months²⁷. In comparison, a modern NGS such as the Illumina HiSeq X is capable of producing up to 16 human genomes worth of data per three-day run. Note that only 1-2% of a human's genetic material codes for genes, in DNA regions called exons. Exomics, which focuses on these smaller regions, leads to quicker and cheaper sequencing^{28,29}. Recently, the ability to perform sequencing of individual cells has provided novel insights into human biology and diseases^{30,31}. Heterogeneity in DNA sequence from one cell to another has unveiled the concept of *mosaicism*, i.e., the presence of two or more populations of cells with different genotypes in one individual³². Cancer in particular has been studied through the lens of genomic variation to find driver mutations.

Epigenomics. Epigenomics is the study of the complete set of epigenetic modifications of the genetic material of a cell. These reversible modifications on DNA or histones affect gene expression and thus play a major role in gene regulation. High throughput methods, such as ChipSeq and Bisulfite sequencing, allow for detection of epigenetic modifications, such as DNA methylation, histone modification and chromatin structure^{33,34}. Epigenomics findings are cell-type specific and epigenetic reprogramming has a clear role in cancer^{35,36}.

Transcriptomics. As opposed to DNA sequence, which is relatively static³⁷, RNA reflects the dynamic state of a cell. Transcriptomics aims at measuring the amount of transcribed genetic material over time. It includes both coding and non-coding RNAs, whose functions are sometimes unknown³⁸. Co-expressed genes (i.e., with similar expression patterns over time)

³<http://www.asco.org/press-center/advances-treatment-gastrointestinal-cancers-0>




Figure 1. Illustration of various omics data types.

have been shown to be likely regulated via the same mechanisms³⁹ and differential expression patterns are used to identify dysregulated genes in cancer⁴⁰, predict possible drug-targets⁴¹ and cancer outcomes⁴².

Proteomics and interactomics. While transcriptomics considers all transcribed RNAs, proteomics focuses on the produced proteins, after all post-translational modifications (e.g., phosphorylation, glycosylation and lipidation). The human proteome is several order of magnitude larger than the human genome; because of alternative promoters, alternative splicing, and mRNA editing, the $\approx 25,000$ human genes lead to $\approx 100,000$ transcripts; with more than 300 different types of post-translational modifications, the number of resulting proteins is estimated to be larger than 1,800,000⁴³. High-throughput capture of protein sequences is done via mass spectrometry experiments⁴⁴. Interactions amongst proteins, or between proteins and other molecules, are captured with high-throughput techniques, such as yeast-two-hybrid⁴⁵ and affinity-captured coupled with mass spectrometry⁴⁶. Interactomes and protein-protein interactions in particular, were successfully used to identify evolutionarily conserved pathways, complexes and functional orthologs^{47–49}.

Metabolomics, glycomics and fluxomics. A metabolite is any substance produced or consumed during metabolism (all chemical processes in a cell). Metabolomics studies all chemical processes involving metabolites⁵⁰. Metabolic profiles are measured with mass-spectrometry and nuclear magnetic resonance spectrometry. Glycomics is the branch of metabolomics that studies glycomes, the sets of all sugars – free or in more complex molecules such as glycoproteins – in cells. Glycosylation is the most intensive and complex post-translational modification of proteins and glycans are known to be involved in cell growth and development⁵¹, in the immune system⁵², in cell-to-cell communication⁵³, in cancer and microbial diseases^{54,55}. Fluxomics refers to a range of methods in experimental and computational biology that attempt to identify, or predict the rates of metabolic reactions in biological systems⁵⁶.

Phenomics and exposomics. Phenomics is an area of biology measuring phenomes – physical and biochemical traits of organisms – as they change in response to genetic mutation and environmental influences. Genome wide association studies (GWAS) are commonly used for detecting associations between single-nucleotide polymorphisms (SNPs) and common diseases such as heart disease, diabetes, auto-immune diseases, and psychiatric disorders⁵⁷. Exposomics encompasses all human environmental (i.e. non-genetic) exposures from conception onwards. It includes, amongst others, exposure to toxic molecules, drugs and radiation. Exposomics benefits from continuous tracking that is now available for most of the key physiological metrics (blood pressure, heart rhythm, brain waves, etc.) and environmental indices, such as air pollution, pollen count and radiation. Even medical imaging, which was traditionally manually investigated, is now a subject of high-throughput capturing^{14,15}. For example, radiomics (the high-throughput capturing and analysis of medical radio images) recently lead to connectomics, which captures and analyses brain connectivity maps.

Metagenomics. Metagenomics aims at capturing human microbiomes, usually through 16S rRNA sequencing. Our bacterial flora has been shown to play an important role in various medical conditions¹²; for example, the bacterial flora of the intestine is known to modulate the effects of drugs involved in cancer treatments⁵⁸. However, taking into account microbiota is challenging,

as human microbiome consists of circa 100 trillion microbial cells, which is about ten times the number of human cells⁵⁹.

2.2 Biomedical data gets more complex

The complexity of biomedical data grows in two directions: in terms of the number of samples and in terms of heterogeneity.

The growing number of samples. As capturing technologies are becoming faster and cheaper, the number of individuals for whom data is available is quickly increasing. For example, the number of available human genomes/exomes increased almost exponentially during the last decade: the first human exome was released in 2003⁹, while in 2012, 1,092 human genomes were available⁶⁰. Nowadays, the Exome Aggregation Consortium contains 60,706 unrelated human exomes.⁴ The United Kingdom government recently announced the project to map 100,000 human genomes by 2017⁵ and the precision medicine initiative in the US plans to map 1 million human genomes. Note that this increasing number of genome samples will also come at the price of increasing variations in terms of genome quality. Next generation sequencers produce short reads that need to be assembled into genomes. The quality of the assembled genome highly depends on the ratio between the sum of the short read lengths and of the target genomic sequence length. This ratio is called the depth of the sequencing and it is expressed in terms of X (e.g., 2X sequencing means that on average each nucleotide is covered by two short reads). While current sequencing uses $\approx 30X$, a recent study argues that high quality genomes may require $\approx 126X$ (referred as deep sequencing)⁶¹.

Moreover, for the same individual, an increasing number of samples is captured; data can be collected over different tissues, by using single cell genomics⁶², or on different conditions (e.g., before and after treatment). Finally, the time span of available samples is increasing. For example, gene expression can be measured over time to assess the effect of drugs. Recent developments of non-intrusive capturing techniques (e.g., fetal exome sequencing from maternal blood⁶³ and magnetic-resonance-imaging (MRI), capturing brain connectivity maps from unborn babies to adults⁶) will allow collecting information over the whole life span of an individual, which paves the way to personalized medicine from womb to tomb.

Increasing heterogeneity of captured data. The number of different biological entities (e.g., genes, RNAs, proteins, metabolites, drugs, diseases, etc.) for which data can be collected is increasing. The variety of available data is illustrated in Table 1, which presents some of the well established large scale biomedical databases. The collected data are so large that even basic data management is becoming challenging. US healthcare was already storing 150 exabytes (10^{18} Bytes) of data in 2011 and is expected to handle yottabytes of data (10^{24} Bytes) in the next few years⁷.

These datasets are highly heterogeneous; data from the same type can be captured with different technologies having varying coverage, bias and noise robustness (e.g., the different technologies for capturing protein-protein interactions⁶⁴), and the same applies across data types. Moreover, the large number of data sources poses data collection issues coming from the lack of standard format in data repositories (so-called data-extraction problem in Big Data⁶⁵).

3 Machine learning techniques

As described in the previous section, Big Data are of large-scale, diversity and complexity, and as such they require efficient algorithms for extracting knowledge hidden in them. Computational techniques that are used to analyse Big Data are either based on statistical, machine learning (ML), or network-based (NB) methods¹⁰⁴. These methods have already demonstrated great potential in bridging the gap between production and interpretation of big data in precision medicine, but there is still a lot of room for their improvements.

ML methods came into focus of Big Data analysis due to their prominent ability to *collectively mine (integrate)* large-scale, diverse and heterogeneous biomedical data types, a foremost challenge in precision medicine and medical informatics¹⁰⁵. Thus, in this section, we mostly focus on ML methods for data integration, but we also mention some recent statistical and NB methods for data integration.

ML methods can be divided into the following classes (see Fig. 2 for an illustration):

- *supervised methods*, such as classification and regression, take as input training data samples with known labels. A model is learned through a training process that maximises the accuracy of its performance on the training data set. The model is then used for mapping new data samples to existing labels. For example, an input data can comprise patients classified as cases and controls. A model is learned to maximise the difference between cases and controls and then it is applied in classification of new patients. Some of the widely used supervised techniques include Support Vector Machines (SVM)¹⁰⁶, Kernel-based methods¹⁰⁷ and Logistic regression¹⁰⁸.

⁴Exome Aggregation Consortium (ExAC), Cambridge, MA (<http://exac.broadinstitute.org>) [09/2015]

⁵<https://www.gov.uk/government/news/human-genome-uk-to-become-world-number-1-in-dna-testing>

⁶Developing Human Connectome Project, <http://www.developingconnectome.org/project/>

⁷Institute for Health Technology Transformation, <http://ihealthtran.com/big-data-in-healthcare>

	Database	Link	Content
genomic	NCBI Gene ⁶⁶	www.ncbi.nlm.nih.gov/gene	Atlas of 59,500 human genes
	GOA ⁶⁷	www.ebi.ac.uk/GOA	487,409 Gene Ontology annotations for 48,569 human gene products
	ENCODE ⁶⁸	www.encodeproject.org	Functional annotations of coding/non-coding DNA elements
epigenomic	NCBI Epigenomics ⁶⁹	www.ncbi.nlm.nih.gov/epigenomics	5,110 epigenetic modifications
	4DGenome ⁷⁰	4dgenome.int-med.uiowa.edu/	3,095,881 experimental and predicted chromatin interactions
	HEA	www.genboree.org/epigenomeatlas	Atlas of reference epigenomes
	MethylomeDB ⁷¹	www.neuroepigenomics.org/methylomedb	DNA methylomes of human brain cells
transcriptomic	NCBI GEO ⁷²	www.ncbi.nlm.nih.gov/geo	1,912 human gene expression datasets
	Expression Atlas ⁷³	www.ebi.ac.uk/gxa	Differential and baseline gene expression data
	CMAP ⁷⁴	www.broadinstitute.org/cmap	~ 7,000 expression profiles for 1,309 perturbagen compounds
	COXPRESdb ⁷⁵	coxpresdb.jp	Co-expression of 19,803 human genes
	GeneFriends ⁷⁶	genefriends.org	Co-expression of 159,184 human genes and transcripts
proteomic	UniProt ⁷⁷	www.uniprot.org	Information about human proteome (69,693 proteins)
	NeXtProt ⁷⁸	www.nextprot.org	Knowledgebase on 20,066 human proteins
	RCSB PDB ⁷⁹	www.rcsb.org/pdb	Portal to 113,494 biological macromolecular 3D-structures
	HPA ⁸⁰	www.thehpp.org	Maps of human proteome on 44 normal and 20 cancer type tissues
	IntAct ⁸¹	www.ebi.ac.uk/intact	209,852 human protein-protein interactions
	BioGrid ⁸²	thebiogrid.org	215,952 human protein-protein interactions
	I2D ⁸³	ophid.utoronto.ca	183,524 (+ 55,985 predicted) protein-protein interactions
	STRING ⁸⁴	string-db.org	8,548,005 interactions between 20,457 proteins
metabolomic	HMDB ⁸⁵	www.hmdb.ca	Atlas of 41,993 human metabolites
	KEGG Pathway ⁸⁶	www.genome.jp/kegg/pathway	298 human pathways
	SMPD ⁸⁷	www.smpdb.ca	~700 human metabolic and disease pathways
	Reactome ⁸⁸	www.reactome.org	8,770 reactions in 1,887 human pathways
	SugarBindDB ⁸⁹	sugarbind.expasy.org	1,256 interactions between 200 glycans and 551 pathogenic agents
	UniCarbKB ⁹⁰	www.unicarbkb.org	3,740 glycan structure entries and 400 glycoproteins
	KEGG Glycan ⁹¹	www.genome.jp/kegg/glycan/	Glycan metabolic pathways
phenomic, exposomic, metagenomic	OMIM ⁹²	www.omim.org	Catalog of mendelian disorders and over 15,000 genes
	NCBI dbGaP ⁹³	www.ncbi.nlm.nih.gov/gap	Database of genotypes and phenotypes
	GWAS Catalog ⁹⁴	www.ebi.ac.uk/gwas/	Genome wide association studies, assaying ~ 100,000 SNPs
	COSMIC ⁹⁵	cancer.sanger.ac.uk/cosmic	Somatic mutations in cancer, with 3,480,051 coding mutations
	TCGA ⁹⁶	cancergenome.nih.gov	Somatic mutations and expression data for ~ 7,000 human tumors
	DrugBank ⁹⁷	www.drugbank.ca	~ 1,600 approved/illicit/experimental drugs with known gene targets
	PubChem ⁹⁸	pubchem.ncbi.nlm.nih.gov/	~ 2 × 10 ⁸ compounds and substances, with 57,335 gene targets.
	T3DB ⁹⁹	www.t3db.org	~ 3,600 common toxins and environmental pollutants
	FooDB ¹⁰⁰	www.foodb.ca	~ 28,000 food components/additives, with presumptive health effects
	UMCD ¹⁰¹	umcd.humanconnectomeproject.org	1,887 brain connectivity matrices from neuroimaging data
	HCP ¹⁰²	www.humanconnectome.org/data	MRI captured brain connectivity maps of 500 adult individuals
	HMP ¹⁰³	hmpdacc.org	11,000 samples of human microbiomes from 300 adult individuals

Table 1. Available data for human. The databases presented in the first row contain genomic data. The databases presented in the second row contain epigenomic data. The databases presented in the third row contain transcriptomic data. The databases presented in the fourth row contain proteomic data. The databases presented in the fifth row contain metabolomic and glycomic data. The databases presented in the sixth row contain phenomic, exposomic and metagenomic data.

- *unsupervised methods*, such as clustering and dimensionality reduction, take as input unlabelled data set. A model is learned by revealing hidden patterns in the data and organising the data into meaningful subsets. These methods are often used in molecular subtyping of cancer patients, or in discovering of patterns in gene expression data. Some of the widely used unsupervised methods in precision medicine include hierarchical clustering¹⁰⁹, K-means¹⁰⁹ and its generalisations including matrix factorization methods¹¹⁰.
- *semi-supervised methods* take as input a mixture of labelled and unlabelled samples. A model is learned to explain the structure in the data as well as to make new predictions of unlabelled samples. For example, in predicting new drug-disease associations, semi-supervised methods learn known drug-disease associations from labelled samples (i.e., prior knowledge), to predict novel drug-disease associations. This strategy is particularly suitable for data integration, as it can incorporate various data types as prior knowledge. One of the most widely used such method is network-regularised matrix factorization¹¹¹.

Based on the type of data they integrate, the integration methods can be divided into *homogeneous*, where the same type of data, but across multiple perspectives (e.g., experimental studies) is integrated, and *heterogeneous*, where multiple data types in different formats are integrated. The later is computationally more challenging, because it requires a framework that can




Figure 2. A schematic illustration of the two main learning techniques in ML – supervised (left panel) and unsupervised (right panel) learning. Left: In supervised learning a training dataset consists of samples with known class labels, e.g., cases and controls. A model is learned by maximizing the difference between cases and controls and then a label for a new sample is determined. Right: In unsupervised learning all samples are unlabelled. A model clusters samples into different groups based on their similarity.

deal with heterogeneous data without transforming it and losing any information through the transformation. A majority of the existing frameworks cannot cope with this issue and they require a pre-processing step prior to integration, where they transform the data into a single representation. In Section 3.2, we discuss this issue in more detail and identify methods capable of addressing this problem.

We survey recent integrative methods for disease sub-typing, biomarker discovery and drug repurposing, and provide a summary listing computational tools that can be used by domain scientists for analysing of Big Data (see Table 2 for the list of methods). The presented methods are chosen based on the following criteria: (1) the method is integrative (i.e., it considers more than one data type) and is applied on biomedical Big Data; (2) the method is predominantly based on Machine Learning (ML) techniques, although we also consider couple of network-based methods; and (3) the method has been used to address one of the the four different precision medicine challenges (see Section 1).

3.1 Computational methods for disease sub-typing and bio-marker discovery

Disease sub-typing (or disease stratification) is a task of grouping patients into subgroups based on genomic, transcriptomic, epigenomic and clinical data. The main goal of sub-typing is achieving more accurate prognoses of individuals' expected outcomes that can be used to improve treatment decisions. Treatments of many diseases have benefited from sub-typing, including Parkinson's, cardiovascular, autoimmune diseases and cancer¹¹².

Cancer is one of the most studied diseases by sub-typing. It is a disease in which genome aberrations are accumulating and eventually leading to dysregulation of the cellular system. Histologically similar cancers are composed of many molecular subtypes with significantly different clinical behaviours and molecular complexity at the genomic, epigenomic, transcriptomic and proteomic levels. Many sub-types have been identified by utilising techniques for data integration for various cancer types, including colon and rectal¹¹³, breast¹¹⁴ and ovarian cancer¹¹⁵.

Unsupervised clustering ML methods, such as hierarchical clustering¹¹⁶, k-means¹¹⁷, consensus clustering¹¹⁸ and non-negative matrix factorization¹¹⁹ have mostly been applied to gene expression data, by comparing expression levels of disease genes across different samples to identify meaningful subgroups. The most recent of such methods propose to divide patients into clinically relevant subtypes by comparing differentially expressed genes (based on normal and cancer tissue samples)¹¹⁶. Based on the selected set of differentially expressed genes, they calculate the distance between patients and perform hierarchical clustering¹⁰⁹. Using mRNA expression data of breast and lung cancer patients, they identified four breast cancer and five lung cancer subtypes with significantly different survival rates. Moreover, instead of identifying individual driver mutations, they identify driver mutation modules for each individual subtype. Namely, by using the protein-protein interaction (PPI) network and by mapping the top 15 most frequently mutated genes of each identified subtype onto the network, they search for an optimally connected sub-network covering these genes. The identified sub-networks are postulated as driver modules that can serve as new targets for repurposing of known drugs and their combinations¹¹⁶. Many other studies have also focused on developing methods for identifying aberrant network modules and pathways by utilizing molecular networks and other omics data. For example, Alcaraz *et al.*¹²⁰ developed KeyPathwayMiner, a method for extraction of aberrant network modules from PPI network by integrating gene expression and DNA methylation data. The authors demonstrated the performance of KeyPathwayMiner on TCGA colorectal cancer patients. The method uses heuristic techniques based on *ant colony optimization*

to extract maximally connected sub-networks with a certain number of differentially expressed genes in all patients. The resulting sub-networks was shown to be enriched in genes with over active signalling in colorectal cancer that can be interpreted as potential therapeutic targets. Similarly, Vaske *et al.*¹²¹ developed PARADIGM, a method for inferring patient-specific altered molecular pathways. The methods also allows for identification of common altered pathways among different patients and thus providing patient sub-typing. The authors applied PARADIGM on TCGA gene expression and DNA copy number variations data of glioblastoma multiforme patients; based on the significant pathway perturbations the authors divide patient into four different subgroups with significantly different survival outcome.

However, a majority of recent methods use integrative approaches to combine multiple types of molecular data, such as DNA copy number alteration, DNA methylation, mRNA and protein expression, and molecular interaction data, accounting for different levels of variations among affected individuals and thereby providing more accurate sub-typing^{122,123}. For example, Shen *et al.*¹²⁴ developed iCluster, an unsupervised learning framework that can simultaneously perform clustering, data integration, feature selection and dimension reduction of multiple data types. It uses a probabilistic matrix factorization approach to simultaneously decompose data matrices, representing different data types (e.g., DNA methylation, DNA copy number variations, mRNA expression data) over the same number of samples (patients), into a common feature space represented by two low-dimensional matrices (Fig. 3(A)). Specifically, they decompose the data matrices by simultaneously factorizing each data matrix into a product of two low-dimensional matrices. The dimensionality of the low-dimensional matrices represents the number of cancer subtypes and it is a predefined parameter. The first matrix, also called *the coefficient matrix*, is specific to each data type, while the second matrix, also called *the cluster indicator matrix*, is shared across the decomposition. The second matrix captures the dependencies across the data types, and based on its entries it is used for a single, integrated assignment of tumor samples to clusters (subtypes). The authors applied iCluster on DNA copy number variation and gene expression data to stratify breast and lung cancer patients. After obtaining the probabilistic representation of the low-dimensional, cluster indicator matrix, they assign tumor samples to different subgroups. In both the breast and lung cancer data examples, they identify novel subgroups with statistically different clinical outcomes as a result of combined information from the both data types¹²⁴.




Figure 3. Illustration of MF-based methods. (A) Matrix factorization of multiple data matrices, X_i , representing different data types (e.g., mRNA expression, DNA methylation, copy number variation, etc.) over the same number of samples p . The matrices are decomposed into a common feature space, represented by matrix Z , that is also a cluster indicator matrix; it is used for assigning p samples into k clusters. Matrices W_i called coefficient matrices are specific to each data set i . (B) Tri-factorization of the data matrix R representing relations between two data sets of sizes n_1 and n_2 (e.g., drug-target interactions) into three low-dimensional matrices. Matrices G_1 and G_2 are cluster indicator matrices for the first and second dataset respectively; matrix G_1 (G_2) is used for assigning n_1 (n_2) data points to k_1 (k_2) clusters. Matrix S is the low-dimensional representation of R .

iCluster is a widely used tool and it has been applied for subtyping of various cancers. For example, Curtis *et al.*¹²⁵, applied it to breast cancer patients from METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) cohort and identified ten subgroups with significantly different outcomes. Moreover, they reported significant correlation between genome variations and gene expression data and based on that, they discovered novel putative genes for breast cancer¹²⁵. iCluster was also applied on TCGA glioblastoma multiforme (the most common and most aggressive malignant brain tumor) data set by simultaneous clustering of DNA copy number variation, methylation and gene expression data¹²⁶. The authors reveal three distinct tumor subtypes of glioblastoma multiforme, as opposed to the four distinct subtypes reported by previous studies that used solely gene expression data²². This demonstrates the power of integrative analysis over analyses of single data types in characterising, classifying and predicting clinical outcomes of cancer patients.

The first method that deals with detection of contradictory signals across different data types is proposed by Yuan *et al.*¹²⁷. They propose a Patient Specific Data Fusion (PSDF) method based on non-parametric Bayesian approach to integrate gene expression and copy number variation data of prostate and breast cancer patients¹²⁷. A Bayesian approach is a statistical

ML approach that builds a model of data by constructing conditional dependencies between data variables represented by conditional probabilities. One of the widely used methods for learning conditional probabilities is Markov chain Monte Carlo (MCMC) technique¹²⁸. Unlike other methods, this method successfully detects contradictory signals between different data types arising from different measurement errors. Specifically, a latent variable is assigned to each patient; it measures whether or not the patient's data are concordant (i.e., in agreement) across different data types. This approach allows for contradictory data information to be suppressed in the patient clustering assignment. The biggest drawback of this approach is that it does not scale well with the number of data types and thus, the authors restrict their analysis only on two data types. Namely, the MCMC step is computationally the most intensive and requires around 48 hours for a single MCMC chain to complete. Despite this drawback, the authors report a novel subtype of prostate cancer patients with extremely poor survival outcome¹²⁷.

To further take into account data inconsistency across data types, iCluster was further generalised by Ray *et al.*¹²⁹ by introducing Bayesian joint factor model built upon iCluster framework. Namely, instead of having a single cluster indicator matrix common for all data types, they further decompose it into shared and data-specific matrix components. Specifically, the cluster indicator matrix is represented as a sum of data type specific and common low-dimensional feature matrices. The common and specific low-dimensional matrices are learned jointly via simultaneous decomposition of all data matrices. This generalisation was shown to be particularly useful for joint analysis of multi-platform genomic data, as it allows more flexibility in the decomposition of distinct data types. Moreover, the authors reported better performance of their model compared to iCluster, because unlike iCluster, that enforces all tumor samples to be included into the clustering procedure, the proposed model can selectively choose between more and less correlated samples across data types when performing clustering assignment. The authors demonstrated their method on TCGA gene expression, copy number variation and methylation data of ovarian cancer patients, particularly for uncovering key driver genes in ovarian cancer¹²⁹. Similarly, Lock *et al.*¹³⁰ introduced JIVE (Joint and Individual Variation Explained), a method which instead of having the same coefficient matrices for shared and data-specific components proposed a model with different coefficient matrices corresponding to joint and data-specific components capturing low-dimensional joint variations across data types, as well as variations specific to each data type. With this extension, JIVE performed a better characterisation of tumor subtypes, as well as a better understanding of the biological interactions between different data types¹³⁰.

To overcome scalability drawbacks of the previous ML clustering methods, that operate with high-dimensional gene \times patient matrices, Wang *et al.*¹³¹ proposed a network-based method that integrates data represented by patient \times patient matrices. This method, called Similarity Network Fusion (SNF), combines mRNA expression, DNA methylation and microRNA expression data for the same set of cancer patients. First, for each data type, it constructs a weighted network of patients, with nodes being patients and weighted links being similarities between patients. The similarities are computed based on their gene profiles for a particular data type. Second, it normalises weights of each network by taking into account the networks from all data types. Finally, it fuses all the networks into a single network by performing a diffusion of information within each network and across different networks. After the convergence of the diffusion process, the authors use a spectral clustering method¹³² on the final fused network to group patients into clusters. Unlike the previous methods, SNF is more scalable. Namely, instead of processing large-scale matrices constructed over a large number of genes, SNF method fuses much smaller matrices representing networks constructed over patients (i.e., samples), which makes the convergence faster. SNF is shown to be robust to noise and when applied on five different cancer types from TCGA database, it was shown to be effective in prediction of patient survival outcomes¹³¹.

A majority of studies are based on analysing mRNA expression data from RNA sequencing and microarrays, and DNA copy number alteration data. Because of noisiness of these data, the patient stratification studies for cancer types often do not produce patient subgroups that agree well with any clinical, or survival data¹¹³. To overcome these shortcomings, Hofree *et al.*¹³³ recently proposed the use of somatic mutation data as a new source of information for cancer patient stratification. However, highly heterogeneous somatic mutation profiles between different patients make the use of somatic mutations for patient stratification into subtypes much harder^{115,133,134}. Namely, two clinically identical tumors rarely have a large set of common mutated genes. Moreover, very few genes are frequently mutated across tumor samples. However, despite this genetic diversity between tumor samples, the perturbed pathways are often similar¹³⁴. Therefore, Hofree *et al.*¹³³ proposed to address this problem by integrating somatic mutations with molecular networks that contain pathways. Their method, called Network-based Stratification (NBS), is based on network-regularised non-negative matrix factorization¹³⁵. Namely, they factorize patient-gene binary matrix, encoding patients' somatic mutation profiles, into a product of two low-dimensional, non-negative matrices; the second of which being the cluster indicator matrix. The non-negativity constraint provides an easier interpretation of clustering assignment of tumor samples. They further incorporate molecular networks into the clustering procedure by constraining the construction of the cluster indicator matrix to respect the local network connectivity. This semi-supervised approach uses molecular networks as prior knowledge about clusters, ensuring that the patients are grouped not only based on the similarity of their somatic mutation profiles, but also based on the proximity of their mutated genes in the molecular network. Using the consensus clustering method¹¹⁸ applied on the final cluster indicator matrix, the authors stratify patients into different

subgroups. The method was applied on ovarian, uterine and lung cancer patients from TCGA database, and it yielded cancer subtypes with different clinical outcomes, response to therapies and tumor histologies.

MF-based methods are promising for mining heterogeneous datasets. These methods have a potential to incorporate any number and type of heterogeneous data and to perform comprehensive analyses. We recently made a step towards this goal and extended the NBS method to incorporate drug data into the framework¹³⁶. Unlike the previous, our method is more comprehensive because it can simultaneously perform three tasks: cancer patient subtyping, drug repurposing and biomarker discovery (driver gene identification). We used Graph-regularized Non-negative Matrix Tri-Factorization (GNMTF)¹¹¹ (see Fig. 3(B) for an illustration) approach to integrate somatic mutation profiles of ovarian cancer patients, molecular networks, drug-target interactions and drug chemical similarity data. We simultaneously tri-factorize patient-gene and drug-target matrix by sharing common low-dimensional matrix factors representing cluster indicator matrices. We compute three different cluster indicator matrices used for clustering assignment of genes, patients and drugs, respectively. The computation of the gene cluster indicator matrix is constrained by connectivity of integrated molecular network, whereas the computation of the drug cluster indicator matrix is constrained by drug chemical similarities. The integrated network is composed of three different molecular networks, namely, PPI, genetic and metabolic interaction networks. Given that GNMTF is both a co-clustering and dimensionality reduction approach, we use GNMTF to perform the following three tasks; 1) we use the patient cluster indicator matrix to stratify ovarian cancer patients into different subgroups with different clinical outcomes; 2) we use the gene cluster indicator matrix to uncover gene modules enriched in driver mutations and postulate new genes as drivers of tumor progression; and 3) we use the matrix completion property of the drug-target matrix to predict novel drug-target interactions and discover new drug candidates that can be repurposed to treat ovarian cancer patients.

Challenges and open questions. Identification of disease subtypes has been shown to be both data and method dependent. Moreover, there is no consensus in the literature about the number of subtypes of a particular cancer type. Depending on the methods and data types they use, different studies report different numbers of subtypes of a particular cancer type (e.g., breast cancer). Also, unsupervised methods require the number of subtypes to be predetermined. Determining the number of subtypes is not a straightforward task and different approaches can be used to discover the correct number of clusters in the data. For example, iCluster uses a cross-validation technique¹²⁴, while NBS determines the number of subtypes based on the stability of the consensus clustering¹³³. Furthermore, there is an urgent need for a reference data set that should be used in future studies for systematic evaluation and comparisons of methods.

Moreover, many of the above mentioned integrative methods for subtyping are incapable of simultaneously considering different data types. For example, SNF method can only integrate data types given by continuous variables (e.g., mRNA expression levels), as they can be easily used for construction of similarity networks. However, SNF cannot incorporate somatic mutation profiles, as it cannot construct a similarity network from highly heterogeneous somatic mutation profiles. Namely, due to the small overlap between somatic mutation profiles across different patients, it is difficult to define a proper similarity measure between patients. Approaches such as NBS and GNMTF are more convenient for integration of somatic mutation profiles. Very few studies integrate somatic mutation data with mRNA and methylation data, due to the difficulty in integrating binary with continuous data types¹³⁷.

A proper normalisation of different data types is another issue in integrative data analyses. If not properly accounted for it often results in cases where the largest data set wins. Unlike iCluster, JIVE properly takes into account the data normalisation problem¹³⁰.

3.2 Computational methods for drug repurposing and personalised treatments

Various computational methods for drug repurposing have been proposed and they can be classified under different criteria. For example, from the data viewpoint, Dudley *et al.*¹⁴⁸ suggested classification into *drug-based* and *disease-based* methods. The first group of methods uses some notion of similarity between drugs (e.g., chemical similarity¹⁴⁹, similarity between gene expressions induced by drug actions⁷⁴, or drug-side effect similarity¹⁵⁰) to group drugs and infer a novel drug candidate for repurposing from the group that can perform the same action as other drugs in the group. The second group of methods uses similarities between diseases (e.g., phenotype similarity¹⁵¹, or similarity between disease symptoms¹⁵²) to group diseases and to infer a novel drug for repurposing by expanding known associations between the drug and some members of the group to the rest of the group. Other approaches use *target-based* similarities¹⁵³, i.e., protein sequence similarity¹⁵⁴, or 3D structural similarity¹⁵⁵, to infer novel drugs. On the other hand, all three approaches can be classified as *similarity-based approaches*¹⁵³. They often use either machine-learning, or network-based methods in the drug inference process. Other computational approaches include *molecular docking simulation* approaches that deal with prediction of a binding place of a drug within protein 3D structure¹⁵⁶. However, the biggest limitations of these methods are the lack of knowledge of 3D structures for many protein targets and extensive computational costs for testing a single drug-target interaction.

A full review of similarity-based and molecular docking approaches for single data type analyses is beyond the scope of this article and we refer the reader to recent review articles by Li *et al.*¹⁵⁷ and Ding *et al.*¹⁵³. Here, we focus on integrative

Method name	Description	Underlying method	Learning strategy
PSDF ¹²⁷	Patient stratification by integrating DNA copy number variation and mRNA expression data.	Bayesian model	unsupervised
KeyPathwayMiner ¹²⁰	Identification of aberrant sub-networks by integrating PPI network with gene expression and DNA methylation data.	Network-based	semi-supervised
PARADIGM ¹²¹	Inference of patient-specific pathways and patient stratification by integrating DNA copy number variations and mRNA expression data.	Network-based	unsupervised
iCluster ¹²⁴	Cancer patient stratification by integrating copy number variation and mRNA expression data.	Matrix factorization	unsupervised
Joint Bayesian factor ¹²⁹	Driver genes identification by integrating mRNA expression and methylation data.	Matrix Factorization	unsupervised
JIVE ¹³⁰	Cancer patient stratification by integrating mRNA expression and miRNA expression data.	Matrix factorization	unsupervised
SNF ¹³¹	Patient subtyping by integrating patient similarity networks constructed from mRNA expression, DNA methylation and miRNA expression data.	Network-based	unsupervised
NBS ¹³³	Cancer patient stratification by integrating somatic mutation data with molecular networks.	Matrix factorization	semi-supervised
GNMTF ¹³⁶	Patient stratification, drug repurposing and identifications of driver mutations by integrating of somatic mutations, molecular networks, drug-target interactions and drug chemical similarity data.	Matrix factorization	semi-supervised
Joint kernel matrices ¹³⁸	Drug repurposing by integrating of drug chemical structures, PPI network and drug induced gene expression data.	Kernel-based	supervised
PreDR ¹³⁹	Drug repurposing and prediction of novel drug-disease associations by integrating drug chemical structures, drug side-effects and protein target structures.	Kernel-based	supervised
MSCMF ¹⁴⁰	Drug-target interaction prediction by integrating known drug-target interactions along with multiple drug and target similarities.	Matrix factorization	semi-supervised
DDR ¹⁴¹	Drug-disease association prediction by integrating known drug-disease association along with multiple drug and target similarities.	Matrix factorization	semi-supervised
PREDICT ¹⁴²	Inference of novel drug indications by integrating multiple drug and target similarities.	Logistic regression	supervised
Coupled network propagation ¹⁴³	Drug-disease network inference by integrating drug, disease and gene interaction network, as well as drug-gene and gene-disease association network	Network-based	unsupervised
Network completion ¹⁴⁴	Drug repurposing by integrating drug-target, drug-disease and disease-target networks.	Network-based	unsupervised
SMirN ¹⁴⁵	Inference of drug-miRNA network by integrating cancer related miRNA target gene expression and transcriptional responses to drug compounds.	Kolmogorov-Smirnov	unsupervised
HGLDA ¹⁴⁶	Inference lncRNA-disease network by integrating miRNA-disease associations and lncRNA-miRNA interactions.	Hyper geometric test	unsupervised
Regularised NMF ¹⁴⁷	Disease causing lncRNA prioritisation by integrating lncRNA-disease associations, along with lncRNA and coding gene expression data and lncRNA-coding gene association data.	Matrix factorization	semi-supervised

Table 2. Summary of methods for integrative analyses in precision medicine. The first group of methods is used for sub-typing and biomarker discovery; the second group is used for drug repurposing and therapy prediction. Some methods can be belong to both categories (e.g., GNMTF).

methods capable of integrating various similarities from different data types containing complementary information, such as pharmacological, chemical, genetic and clinical data. Namely, due to heterogeneity and complexity of many diseases characterised with different subtypes, drugs are not always equally efficient in treatment of the same disease. Thus, the overarching goal of precision medicine is to take into account molecular diversity between individuals when diagnosing patients and prescribing drugs specific to each individual¹⁵⁸. With the Big Data initiative (see Section 2), integrative computational approaches have started attracting more attention due to their ability to address this goal.

For example, Napolitano *et al.*¹³⁸ used a kernel-based (KB) method¹⁰⁶ to integrate drug chemical similarity, PPI network and drug induced gene expression data after a patient treatment. Each data is represented by a kernel matrix in a drug-centered feature space. Particularly, the three kernel matrices represent drug-drug similarities based on: 1) drug chemical structures from DrugBank; 2) proximity of their targets in the PPI network; and 3) correlations between gene profiles under the drug's influence retrieved from CMap database. After combining these kernel matrices into a single kernel matrix, the authors applied a Support Vector Machine (SVM), a supervised machine learning method for classification. They trained the SVM on the existing drug classification achieving 78% of classification accuracy and they used the top scoring misclassified drugs as new candidates for repurposing¹³⁸. A similar approach was used by Wang *et al.*¹³⁹, who developed a PreDR (**P**redict **D**rug **R**epurposing) method where drug-centered kernel matrices represent: 1) drug chemical similarities obtained from PubChem database; 2) target (protein) sequence similarities retrieved from KEGG BRITE and DrugBank; and 3) drug side-effect similarities for

SIDER database. The disease-centered kernel matrix represents disease similarities measured by their semantic similarity of disease phenotypes retrieved from OMIM database. The authors trained the SVM classifier on the combined kernel matrix and reported accuracy in identifying novel drug-disease interactions.

Zheng *et al.*¹⁴⁰ developed an integrative framework called Multiple Similarities Collaborative Matrix Factorization (MSCMF) for drug-target prediction. It takes as an input a matrix representing drug-target interactions, as well as multiple matrices representing different types of similarities between drugs and targets constructed from various databases. MSCMF projects drugs and targets into a common low-dimensional feature space by factorizing the drug-target matrix into a product of two low-dimensional matrices representing drug and target low-dimensional feature vectors, respectively. The computation of low-dimensional matrices of drugs and targets is done in a semi-supervised manner by constraining their values to be consistent with drug-drug and target-target similarity matrices, respectively. Namely, the similarity between two drugs is approximated by the inner product of their corresponding feature vectors. The same is applied on target feature vectors. The authors mathematically formulated the factorization condition and constraints within the same objective function, which they minimise by applying the Alternating Least Squares (ALS) algorithm¹⁵⁹. After convergence, they reconstructed the drug-target matrix from the obtained low-dimensional matrices (i.e., from matrix completion) and extracted new, previously unobserved entries representing predicted drug-target interactions. MSCMF is shown to perform better than the previous state-of-the-art methods for drug-target prediction. Moreover, the big advantage of MSCMF over the previous methods is the fact that it can integrate similarities from multiple data sources over the same set of drugs or targets and estimate their influence onto the quality of the drug-target prediction.

Similar to MSCMF, Zhang *et al.*¹⁴¹ proposed DDR (Drug Disease Repositioning), a semi-supervised, matrix tri-factorization-based framework for novel drug-disease association prediction. It takes as input known drug-disease associations, as well as multiple drug and multiple disease similarity networks and generates new drug-disease associations. In particular, it constructs three drug similarity matrices based on their chemical structures, side-effects and target proteins and three disease similarity matrices based on their phenotypes, Disease Ontology and disease genes. The predicted associations are validated in clinical trial databases. Unlike MSCMF, DDR factorizes drug-disease associations into a product of three low-dimensional matrices, where the first and the last matrices can be interpreted as cluster assignment matrices of drugs and diseases, respectively. These matrices can be used to identify subgroups of highly correlated drugs and diseases, thus providing additional insights for drug repurposing by identifying a group of similar drug candidates that can be used in clinical trials.

Gottlieb *et al.*¹⁴² developed a supervised method, called PREDICT (PREdicting DRug IndiCaTions). First, it computes drug-drug and disease-disease similarity measures from five and six different drug and disease data sources, respectively. Second, based on these similarities, it constructs an overall similarity for each drug-disease pair. Finally, based on the drug-disease similarity, it trains a logistic regression classifier on correctly classifying known drug-disease associations. The authors demonstrated a great accuracy of PREDICT in identifying novel indications of drugs with Area Under the ROC curve (AUC)¹⁶⁰ of 0.92. Moreover, they propose PREDICT as a general framework that can be used in future personalized drug treatments by incorporating gene expression data of disease patients into the framework.

All previous methods use either supervised, or semi-supervised strategy in predicting drug-target, or drug-disease associations and thus, they require a gold standard (i.e., a set of known associations) to train their models. For many specific diseases, that data set is unknown, or incomplete, which makes the use of the methods more difficult. To overcome this, Huang *et al.*¹⁴³ proposed a completely unsupervised integrative method that can infer drug-disease associations without any prior associations. They used coupled network propagation¹⁶¹ on drug-drug chemical similarity, disease-disease phenotype similarity and gene-gene co-expression similarity homogeneous networks, connected by drug-gene and gene-disease heterogeneous networks. They applied their method on data for prostate and colorectal cancer patients. They identified top scoring drugs predicted to be used in treatment of these groups of patients. **Another unsupervised, network-based method for heterogeneous network integration and drug repurposing was introduced by Daminelli *et al.*¹⁴⁴. They predicted novel drug-target associations by completing incomplete bi-cliques in the integrated drug-target-disease network. They demonstrate the power of their method by predicting novel drugs for cardiovascular and parasitic diseases, as well as by predicting novel drugs for cancer-related kinases. For other network-based methods for drug repurposing we refer a reader to a recent review paper by Wu *et al.*¹⁶².**

Non-coding RNAs, in particular microRNAs (or miRNAs) and long non-coding RNAs (lncRNAs), have recently started attracting attention due to their involvement in various diseases, including cancer and autoimmune disorders¹⁶³ and thus, have been proposed as potential biomarkers^{146,164} and drug targets^{165,166}. Due to large collections of transcriptional and drug data being available, new computational methods for identification of miRNAs as potential drug targets have recently been proposed. For example, Jiang *et al.*¹⁴⁵ proposed a framework for construction of a network, SMirN, of interactions between small drug molecules (compounds) and miRNAs using data from different human cancers. Specifically, they used transcriptional responses to compounds and differentially expressed miRNA target genes in 23 different human cancers. For each miRNA, they partitioned their target genes into GO modules, and for each GO module they evaluated the association between its differentially expressed target genes and the transcriptional response to the compound by using Kolmogorov-Smirnov test. If

these associations are confirmed for a significant number of GO modules of a particular miRNA, then the authors hypothesized a link between the miRNA and the corresponding drug compound. They analysed the SMirN network and separately grouped miRNAs and compounds into modules, based on which they infer novel potential miRNA targets, as well as novel drug compounds that can be used in drug repurposing for cancer therapy. Chen¹⁶⁷ developed a novel model of HyperGeometric distribution for lncRNA-Disease Associations (HGLDA) inference. The model integrates known miRNA-disease associations and lncRNA-miRNA interactions and without a gold standard data set, it infers a network of lncRNA-disease associations with AUC of 0.76 in the leave-one-out cross validation. Based on the top 19 predicted associations, they reported novel lncRNAs involved in breast, lung and colorectal cancer that can be used as novel biomarkers for diagnosis of these cancers. A more sophisticated integrative method, based on non-negative matrix factorization, was recently proposed by Biswas *et al.*,¹⁴⁷. They factorize lncRNA-disease association matrix into a product of two non-negative, low-dimensional matrices specific to lncRNAs and diseases, respectively. The non-negativity of the obtained, low-dimensional matrices allows for easier extraction of lncRNA and disease subgroups in the data. They can also be interpreted as cluster assignment matrices for lncRNAs and diseases, respectively. The factorization of the lncRNA-disease association matrix was done in a semi-supervised way, by constraining the construction of the low-dimensional matrices with additional data, including coding gene and lncRNA expression data, as well as lncRNA-coding gene association network. The authors identified several biologically relevant lncRNA and disease groups. Based on the membership scores in the lncRNA low-dimensional matrix, they ranked disease causing lncRNAs for each particular disease. They identified a prominent group of lncRNAs associated with heart diseases, as well as a group of lncRNAs strongly associated with neurological disorders that can be used in future experimental testing as biomarkers of these disorders.

Challenges and open questions. Many of the methods presented in this section require different data types to be represented in common feature space. For example, KB methods (e.g., PreDR) require the matrices of all data types to be constructed over the same set of entities (e.g., drugs, or diseases). This often requires transforming the data that may lead to information loss. On the other hand, MF-based methods (e.g., MSCMF) can handle these heterogeneous data without any data transformation and thus, without any information loss. Also, many methods require choosing an appropriate similarity measure to integrate various data types. This is not always a straightforward task and different measures may result in different final conclusions.

Similar to the methods described in section 3.1, the methods for drug-target (and drug-disease) prediction and drug repurposing are lacking a reference corpus of data for comparing their performances.

4 Challenges and perspectives

As presented in Section 2, biomedical data are increasingly becoming available and dealing with their “three V” components will impose many challenges and open questions. For example, in addressing Big Data’s volume (i.e., high dimensionality), many dimensionality reduction techniques have been devised, reviewed in Sections 3.1 and 3.2. However, they are all computationally intensive on large-scale data sets and devising techniques that are both efficient and accurate in revealing hidden substructures in them is still an open question. One of the possible solutions to addressing this question might be Topological Data Analysis methods (TDAs)^{168,169}. TDAs use mathematical concepts developed in algebraic topology. TDAs analyse Big Data by converting them into low-dimensional geometric representations from which they extract shapes (patterns) and obtain insight into them. These methods have been shown to be more efficient in finding substructures in large-scale data sets than standard methods, such as clustering, or principal component analysis methods. Moreover, they succeed in finding hidden structures in the data that standard methods failed to discover¹⁶⁹.

Dealing with Big Data’s velocity (i.e., coping with its growth over time) is particularly challenging and poorly addressed in the literature on precision medicine. One of the possible future directions in addressing this challenge is the utilisation of so-called “anytime algorithms”¹⁷⁰ that can learn from streaming data (e.g., time-dependent Bayesian classifiers)¹⁷¹ and that still return a valuable result if their execution is interrupted at any time. Moreover, in the future, we will have access to more and more time series data. At the moment, such time series are either pre-processed to find patterns, e.g., time series of expression data are either used to find genes with time-correlated expression (co-expression network), or used to study the effect of drugs on short time scales by differential expression analysis. With the increasing number of measured features and the increasing time span of the measurements, a key challenge will be to find a data integration model that will directly mine time series measurements for which the time spans and frequencies of measurements vary greatly.

The Big Data’s variety (i.e., heterogeneity) has been addressed by many methods as presented in Section 3.2. MF-based methods are promising for mining heterogeneous datasets. Although GNMTF is a versatile data integration framework¹³⁶, its computational complexity increases with the number of data types to be integrated. Thus, integrating large numbers of heterogeneous data types within the MF-based framework necessitates novel algorithmic improvements.

Extracting complementary information conveyed in data of different formats and types is another challenge that is partially addressed by the presented integrative methods. For example, proteomics data have been shown to be a good complement to other omics data. Namely, many studies have confirmed that proteins having physical interactions in a PPI network are more

likely to have correlated co-expression profiles of their corresponding genes¹⁷². On the contrary, protein physical interactions are less likely to coincide to genetic interactions (GI) of the their corresponding genes¹⁷³. Thus, integrating GI network with PPI network and other molecular networks has been shown to be beneficial in many biological problems^{133,136,174}.

Moreover, many data types including exposomics and metagenomics data are yet to be analysed and their integration with other data will be a focus of future studies. For example, much of an individual's health data, such as demographic data, personal and family medical history, vaccination records, laboratory tests and imaging results are systematically being collected and stored in Electronic Health Records (EHR). EHR data are increasingly becoming available for academic research purposes and they present numerous computational challenges that are yet to be addressed. Two major computational challenges include developing algorithms for: 1) individual *phenotyping* (i.e., annotating patient records with disease conditions)¹⁷⁵ and 2) integration of EHR data with omics data for better understanding of disease mechanisms and treatments¹⁷⁶. The biggest obstacles of the first challenge are nosiness and incompleteness of the EHR data that needs to be properly taken into account. On the other hand, the biggest obstacles of the second challenge are heterogeneity and different format types of EHR and genomic data. Some steps towards addressing these challenges have been made^{175,176}, but developing methods that can overcome these obstacles are yet to come.

Finally, while we focus on the four challenges of precision medicine, big data integration also opens novel opportunities in bioinformatics and in other data sciences. For example, it can be used to reprocess raw data in more coherent way, or with novel research questions in mind¹⁷⁷.

References

1. Hood, L. & Friend, S. H. Predictive, personalized, preventive, participatory (p4) cancer medicine. *Nature Reviews Clinical Oncology* **8**, 184–187 (2011).
2. Mirnezami, R., Nicholson, J. & Darzi, A. Preparing for precision medicine. *New England Journal of Medicine* **366**, 489–491 (2012).
3. Table of blood group systems v4.0 (2014).
4. Smits, J., De Meester, J., Persijn, G., Claas, F. & Vanrenterghem, Y. Long-term results of solid organ transplantation. report from the eurotransplant international foundation. *Clinical transplants* 109–127 (1995).
5. Takemoto, S., Terasaki, P. I., Cecka, J. M., Cho, Y. W. & Gjertson, D. W. Survival of nationally shared, hla-matched kidney transplants from cadaveric donors. *New England Journal of Medicine* **327**, 834–839 (1992).
6. Thorogood, J. *et al.* The effect of hla matching on kidney graft survival in separate posttransplantation intervals. *Transplantation* **50**, 146–149 (1990).
7. Mitsuishi, Y. & Terasaki, P. Hla matching effect on five-year graft survival and half-life in the cyclosporine era. *Kidney international. Supplement* **38**, S172–5 (1992).
8. Beyer, M. A. & Laney, D. The importance of 'big data': a definition. *Stamford, CT: Gartner* (2012).
9. Consortium, I. H. G. S. *et al.* Finishing the euchromatic sequence of the human genome. *Nature* **431**, 931–945 (2004).
10. McDermott, J. E. *et al.* Challenges in biomarker discovery: combining expert insights with statistical analysis of complex omics data. *Expert opinion on medical diagnostics* **7**, 37–51 (2013).
11. Kato, H., Takahashi, S. & Saito, K. Omics and integrated omics for the promotion of food and nutrition science. *Journal of traditional and complementary medicine* **1**, 25 (2011).
12. Cho, I. & Blaser, M. J. The human microbiome: at the interface of health and disease. *Nature Reviews Genetics* **13**, 260–270 (2012).
13. Yuan, Y. *et al.* Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. *Science translational medicine* **4**, 157ra143–157ra143 (2012).
14. Kumar, V. *et al.* Radiomics: the process and the challenges. *Magnetic resonance imaging* **30**, 1234–1248 (2012).
15. Lambin, P. *et al.* Radiomics: extracting more information from medical images using advanced feature analysis. *European Journal of Cancer* **48**, 441–446 (2012).
16. Ahrens, M. B., Orger, M. B., Robson, D. N., Li, J. M. & Keller, P. J. Whole-brain functional imaging at cellular resolution using light-sheet microscopy. *Nature methods* **10**, 413–420 (2013).
17. Mardis, E. R. The 1,000genome, the 100,000 analysis. *Genome Med* **2**, 84 (2010).
18. Margolis, R. *et al.* The national institutes of health's big data to knowledge (bd2k) initiative: capitalizing on biomedical big data. *Journal of the American Medical Informatics Association* **21**, 957–958 (2014).

19. Lötvall, J. *et al.* Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. *Journal of Allergy and Clinical Immunology* **127**, 355–360 (2011).
20. Boland, M. R., Hripcsak, G., Shen, Y., Chung, W. K. & Weng, C. Defining a comprehensive verotype using electronic health records for personalized medicine. *Journal of the American Medical Informatics Association* **20**, e232–e238 (2013).
21. Schulam, P., Wigley, F. & Saria, S. Clustering longitudinal clinical marker trajectories from electronic health data: Applications to phenotyping and endotype discovery. In *Twenty-Ninth AAAI Conference on Artificial Intelligence* (2015).
22. Verhaak, R. G. *et al.* Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in *pdgfra*, *idh1*, *egfr*, and *nf1*. *Cancer cell* **17**, 98–110 (2010).
23. Lewis, S. *et al.* Heterogeneity of parkinson's disease in the early clinical stages using a data driven approach. *Journal of Neurology, Neurosurgery & Psychiatry* **76**, 343–348 (2005).
24. Gutman, S. & Kessler, L. G. The us food and drug administration perspective on cancer biomarker development. *Nature Reviews Cancer* **6**, 565–571 (2006).
25. Davis, J. C. *et al.* The microeconomics of personalized medicine: today's challenge and tomorrow's promise. *Nature reviews Drug discovery* **8**, 279–286 (2009).
26. Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. *Nature reviews Drug discovery* **3**, 673–683 (2004).
27. Wheeler, D. A. *et al.* The complete genome of an individual by massively parallel dna sequencing. *nature* **452**, 872–876 (2008).
28. Ng, S. B. *et al.* Targeted capture and massively parallel sequencing of 12 human exomes. *Nature* **461**, 272–276 (2009).
29. Choi, M. *et al.* Genetic diagnosis by whole exome capture and massively parallel dna sequencing. *Proceedings of the National Academy of Sciences* **106**, 19096–19101 (2009).
30. Owens, B. The single life. *Nature* **491**, 27–29 (2012).
31. Shapiro, E., Biezuner, T. & Linnarsson, S. Single-cell sequencing-based technologies will revolutionize whole-organism science. *Nature Reviews Genetics* **14**, 618–630 (2013).
32. Lupski, J. R. Genome mosaicism—one human, multiple genomes. *Science* **341**, 358–359 (2013).
33. Ziller, M. J. *et al.* Charting a dynamic dna methylation landscape of the human genome. *Nature* **500**, 477–481 (2013).
34. Rivera, C. M. & Ren, B. Mapping human epigenomes. *Cell* **155**, 39–55 (2013).
35. Dawson, M. A. & Kouzarides, T. Cancer epigenetics: from mechanism to therapy. *Cell* **150**, 12–27 (2012).
36. Suvà, M. L., Riggi, N. & Bernstein, B. E. Epigenetic reprogramming in cancer. *Science* **339**, 1567–1570 (2013).
37. Vishwanathan, N., Le, H., Le, T. & Hu, W.-S. Advancing biopharmaceutical process science through transcriptome analysis. *Current opinion in biotechnology* **30**, 113–119 (2014).
38. Marian, A. sequencing your genome: What does it mean? *Methodist DeBakey cardiovascular journal* **10**, 3 (2014).
39. Allocco, D. J., Kohane, I. S. & Butte, A. J. Quantifying the relationship between co-expression, co-regulation and gene function. *BMC bioinformatics* **5**, 18 (2004).
40. DeRisi, J. *et al.* Use of a cDNA microarray to analyse gene expression patterns in human cancer. *Nature genetics* **14**, 457–460 (1996).
41. Volinia, S. *et al.* A microRNA expression signature of human solid tumors defines cancer gene targets. *Proceedings of the National academy of Sciences of the United States of America* **103**, 2257–2261 (2006).
42. Van't Veer, L. J. *et al.* Gene expression profiling predicts clinical outcome of breast cancer. *nature* **415**, 530–536 (2002).
43. Jensen, O. N. Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry. *Current opinion in chemical biology* **8**, 33–41 (2004).
44. Ong, S.-E. & Mann, M. Mass spectrometry-based proteomics turns quantitative. *Nature chemical biology* **1**, 252–262 (2005).
45. Fields, S. & Song, O. K. A novel genetic system to detect protein-protein interactions. *Nature* **340**, 245–246 (1989).
46. Ho, Y., Gruhler, A., Heilbut, A., Bader, G. D. *et al.* Systematic identification of protein complexes in *saccharomyces cerevisiae* by mass spectrometry. *Nature* **415**, 180–183 (2002).

47. Kelley, B. P., Sharan, R., Karp, R. M. *et al.* Conserved pathways within bacteria and yeast as revealed by global protein network alignment. *Proceedings of the National Academy of Sciences* **100**, 11394–11399 (2003).
48. Kuchaiev, O., Milenković, T., Memišević, V., Hayes, W. & Pržulj, N. Topological network alignment uncovers biological function and phylogeny. *Journal of The Royal Society Interface* **7**, 1341–1354 (2010).
49. Bandyopadhyay, S., Sharan, R. & Ideker, T. Systematic identification of functional orthologs based on protein network comparison. *Genome Research* **16**, 428–435 (2006).
50. Daviss, B. Growing pains for metabolomics. *The Scientist* **19**, 25–28 (2005).
51. Lowe, J. B. & Marth, J. D. A genetic approach to mammalian glycan function. *Annual review of biochemistry* **72**, 643–691 (2003).
52. Kinjo, Y. *et al.* Recognition of bacterial glycosphingolipids by natural killer t cells. *Nature* **434**, 520–525 (2005).
53. Crocker, P. R. Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell–cell interactions and signalling. *Current opinion in structural biology* **12**, 609–615 (2002).
54. Sasisekharan, R., Shriver, Z., Venkataraman, G. & Narayanasami, U. Roles of heparan-sulphate glycosaminoglycans in cancer. *Nature Reviews Cancer* **2**, 521–528 (2002).
55. Fry, E. E. *et al.* The structure and function of a foot-and-mouth disease virus–oligosaccharide receptor complex. *The EMBO Journal* **18**, 543–554 (1999).
56. Winter, G. & Krömer, J. O. Fluxomics—connecting ‘omics analysis and phenotypes. *Environmental microbiology* **15**, 1901–1916 (2013).
57. Visscher, P. M., Brown, M. A., McCarthy, M. I. & Yang, J. Five years of gwas discovery. *The American Journal of Human Genetics* **90**, 7–24 (2012).
58. Viaud, S. *et al.* The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. *Science* **342**, 971–976 (2013).
59. Rajendhran, J. & Gunasekaran, P. Human microbiomics. *Indian journal of microbiology* **50**, 109–112 (2010).
60. Consortium, . G. P. *et al.* An integrated map of genetic variation from 1,092 human genomes. *Nature* **491**, 56–65 (2012).
61. Ajay, S. S., Parker, S. C., Abaan, H. O., Fajardo, K. V. F. & Margulies, E. H. Accurate and comprehensive sequencing of personal genomes. *Genome research* **21**, 1498–1505 (2011).
62. Kalisky, T. & Quake, S. R. Single-cell genomics. *Nature methods* **8**, 311–314 (2011).
63. Fan, H. C. *et al.* Non-invasive prenatal measurement of the fetal genome. *Nature* **487**, 320–324 (2012).
64. Chen, Y.-C., Rajagopala, S. V., Stellberger, T. & Uetz, P. Exhaustive benchmarking of the yeast two-hybrid system. *Nature methods* **7**, 667–668 (2010).
65. Jagadish, H. *et al.* Big data and its technical challenges. *Communications of the ACM* **57**, 86–94 (2014).
66. Brown, G. R. *et al.* Gene: a gene-centered information resource at ncbi. *Nucleic acids research* **43**, D36–D42 (2015).
67. Dimmer, E. C. *et al.* The uniprot-go annotation database in 2011. *Nucleic acids research* **40**, D565–D570 (2012).
68. Consortium, E. P. *et al.* The encode (encyclopedia of dna elements) project. *Science* **306**, 636–640 (2004).
69. Bernstein, B. E. *et al.* The nih roadmap epigenomics mapping consortium. *Nature biotechnology* **28**, 1045–1048 (2010).
70. Teng, L., He, B., Wang, J. & Tan, K. 4dgenome: a comprehensive database of chromatin interactions. *Bioinformatics* **31**, 158 (2015).
71. Xin, Y. *et al.* Methylomedb: a database of dna methylation profiles of the brain. *Nucleic acids research* **40**, D1245–D1249 (2012).
72. Edgar, R., Domrachev, M. & Lash, A. E. Gene expression omnibus: Ncbi gene expression and hybridization array data repository. *Nucleic acids research* **30**, 207–210 (2002).
73. Petryszak, R. *et al.* Expression atlas update—a database of gene and transcript expression from microarray-and sequencing-based functional genomics experiments. *Nucleic acids research* **42**, D926–D932 (2014).
74. Lamb, J. *et al.* The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. *science* **313**, 1929–1935 (2006).
75. Okamura, Y. *et al.* Coxpresdb in 2015: coexpression database for animal species by dna-microarray and rnaseq-based expression data with multiple quality assessment systems. *Nucleic acids research* **42**, gku1163 (2014).

76. van Dam, S., Craig, T. & de Magalhães, J. P. Genefriends: a human rna-seq-based gene and transcript co-expression database. *Nucleic acids research* **43**, D1124–D1132 (2015).
77. Consortium, U. *et al.* Uniprot: a hub for protein information. *Nucleic acids research* gku989 (2014).
78. Gaudet, P. *et al.* The nextprot knowledgebase on human proteins: current status. *Nucleic acids research* **43**, D764–D770 (2015).
79. Berman, H. M. *et al.* The protein data bank. *Nucleic acids research* **28**, 235–242 (2000).
80. Uhlén, M. *et al.* Tissue-based map of the human proteome. *Science* **347**, 1260419 (2015).
81. Kerrien, S. *et al.* The intact molecular interaction database in 2012. *Nucleic acids research* gkr1088 (2011).
82. Chatr-aryamontri, A. *et al.* The biogrid interaction database: 2015 update. *Nucleic acids research* gku1204 (2014).
83. Brown, K. R. & Jurisica, I. Online predicted human interaction database. *Bioinformatics* **21**, 2076–2082 (2005).
84. Szklarczyk, D. *et al.* String v10: protein–protein interaction networks, integrated over the tree of life. *Nucleic acids research* gku1003 (2014).
85. Wishart, D. S. *et al.* Hmdb 3.0—the human metabolome database in 2013. *Nucleic acids research* gks1065 (2012).
86. Ogata, H. *et al.* Kegg: Kyoto encyclopedia of genes and genomes. *Nucleic Acids Research* **27**, 29–34 (1999).
87. Jewison, T. *et al.* Smpdb 2.0: big improvements to the small molecule pathway database. *Nucleic acids research* **42**, D478–D484 (2014).
88. Croft, D. *et al.* The reactome pathway knowledgebase. *Nucleic acids research* **42**, D472–D477 (2014).
89. Shakhsher, B. *et al.* Sugarbind database (sugarbinddb): a resource of pathogen lectins and corresponding glycan targets. *Journal of Molecular Recognition* **26**, 426–431 (2013).
90. Campbell, M. P. *et al.* Unicarbkb: building a knowledge platform for glycoproteomics. *Nucleic acids research* gkt1128 (2013).
91. Hashimoto, K. *et al.* Kegg as a glycome informatics resource. *Glycobiology* **16**, 63R–70R (2006).
92. Hamosh, A., Scott, A. F., Amberger, J. S., Bocchini, C. A. & McKusick, V. A. Online mendelian inheritance in man (omim), a knowledgebase of human genes and genetic disorders. *Nucleic acids research* **33**, D514–D517 (2005).
93. Mailman, M. D. *et al.* The ncbi dbgap database of genotypes and phenotypes. *Nature genetics* **39**, 1181–1186 (2007).
94. Welter, D. *et al.* The nhgri gwas catalog, a curated resource of snp-trait associations. *Nucleic acids research* **42**, D1001–D1006 (2014).
95. Forbes, S. A. *et al.* Cosmic: exploring the world’s knowledge of somatic mutations in human cancer. *Nucleic acids research* **43**, D805–D811 (2015).
96. Weinstein, J. N. *et al.* The cancer genome atlas pan-cancer analysis project. *Nature genetics* **45**, 1113–1120 (2013).
97. Law, V. *et al.* Drugbank 4.0: shedding new light on drug metabolism. *Nucleic acids research* **42**, D1091–D1097 (2014).
98. Wang, Y. *et al.* Pubchem: a public information system for analyzing bioactivities of small molecules. *Nucleic acids research* **37**, W623–W633 (2009).
99. Lim, E. *et al.* T3db: a comprehensively annotated database of common toxins and their targets. *Nucleic acids research* **38**, D781–D786 (2010).
100. Scalbert, A. *et al.* Databases on food phytochemicals and their health-promoting effects. *Journal of agricultural and food chemistry* **59**, 4331–4348 (2011).
101. Brown, J. A., Rudie, J. D., Bandrowski, A., Van Horn, J. D. & Bookheimer, S. Y. The ucla multimodal connectivity database: a web-based platform for brain connectivity matrix sharing and analysis. *Frontiers in neuroinformatics* **6** (2012).
102. Van Essen, D. C. *et al.* The wu-minn human connectome project: an overview. *Neuroimage* **80**, 62–79 (2013).
103. Consortium, H. M. P. *et al.* Structure, function and diversity of the healthy human microbiome. *Nature* **486**, 207–214 (2012).
104. Greene, C. S., Tan, J., Ung, M., Moore, J. H. & Cheng, C. Big data bioinformatics. *Journal of cellular physiology* **229**, 1896–1900 (2014).

105. Gligoriević, V. & Pržulj, N. Methods for biological data integration: perspectives and challenges. *Journal of The Royal Society Interface* **XXX**, XX–YY (2015).
106. Vapnik, V. N. & Vapnik, V. *Statistical learning theory*, vol. 1 (Wiley New York, 1998).
107. Scholkopf, B. & Smola, A. J. *Learning with Kernels: Support Vector Machines, Regularization, Optimization, and Beyond* (MIT Press, Cambridge, MA, USA, 2001).
108. Freedman, D. A. *Statistical models: theory and practice* (Cambridge University Press, 2009).
109. Hartigan, J. A. *Clustering Algorithms* (John Wiley & Sons, Inc., New York, NY, USA, 1975), 99th edn.
110. Lee, D. D. & Seung, H. S. Learning the parts of objects by non-negative matrix factorization. *Nature* **401**, 788–791 (1999).
111. Wang, F., Li, T. & Zhang, C. Semi-supervised clustering via matrix factorization. In *SDM*, 1–12 (SIAM, 2008).
112. Saria, S. & Goldenberg, A. Subtyping: What it is and its role in precision medicine. *Intelligent Systems, IEEE* **30**, 70–75 (2015).
113. Network, C. G. A. Comprehensive molecular characterization of human colon and rectal cancer. *Nature* **487**, 330–337 (2012).
114. Network, C. G. A. *et al.* Comprehensive molecular portraits of human breast tumours. *Nature* **490**, 61–70 (2012).
115. Network, C. G. A. R. *et al.* Integrated genomic analyses of ovarian carcinoma. *Nature* **474**, 609–615 (2011).
116. Wang, L., Li, F., Sheng, J. & Wong, S. T. A computational method for clinically relevant cancer stratification and driver mutation module discovery using personal genomics profiles. *BMC genomics* **16**, S6 (2015).
117. de Souto, M. C., Costa, I. G., de Araujo, D. S., Ludermir, T. B. & Schliep, A. Clustering cancer gene expression data: a comparative study. *BMC bioinformatics* **9**, 497 (2008).
118. Monti, S., Tamayo, P., Mesirov, J. & Golub, T. Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. *Machine learning* **52**, 91–118 (2003).
119. Brunet, J.-P., Tamayo, P., Golub, T. R. *et al.* Metagenes and molecular pattern discovery using matrix factorization. *Proceedings of the National Academy of Sciences* **101**, 4164–4169 (2004).
120. Alcaraz, N. *et al.* Keypathwayminer 4.0: condition-specific pathway analysis by combining multiple omics studies and networks with cytoscape. *BMC Systems Biology* **8**, 99 (2014).
121. Vaske, C. J. *et al.* Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using paradigm. *Bioinformatics* **26**, i237–i245 (2010).
122. List, M. *et al.* Classification of breast cancer subtypes by combining gene expression and dna methylation data. *Journal of integrative bioinformatics* **11**, 236 (2014).
123. Kristensen, V. N. *et al.* Principles and methods of integrative genomic analyses in cancer. *Nature Reviews Cancer* **14**, 299–313 (2014).
124. Shen, R., Olshen, A. B. & Ladanyi, M. Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. *Bioinformatics* **25**, 2906–2912 (2009).
125. Curtis, C. *et al.* The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* **486**, 346–352 (2012).
126. Shen, R. *et al.* Integrative subtype discovery in glioblastoma using icluster. *PLoS One* **7**, e35236 (2012).
127. Yuan, Y., Savage, R. S. & Markowitz, F. Patient-specific data fusion defines prognostic cancer subtypes. *PLoS Computational Biology* **7**, e1002227 (2011).
128. Ben-Gal, I. *Bayesian Networks*, chap. 1 (John Wiley & Sons, Ltd, 2008).
129. Ray, P., Zheng, L., Lucas, J. & Carin, L. Bayesian joint analysis of heterogeneous genomics data. *Bioinformatics* **30**, 1370–1376 (2014).
130. Lock, E. F., Hoadley, K. A., Marron, J. & Nobel, A. B. Joint and individual variation explained (jive) for integrated analysis of multiple data types. *The annals of applied statistics* **7**, 523 (2013).
131. Wang, B. *et al.* Similarity network fusion for aggregating data types on a genomic scale. *Nature methods* **11**, 333–337 (2014).

132. Ng, A. Y., Jordan, M. I., Weiss, Y. *et al.* On spectral clustering: Analysis and an algorithm. *Advances in neural information processing systems* **2**, 849–856 (2002).
133. Hofree, M., Shen, J. P., Carter, H., Gross, A. & Ideker, T. Network-based stratification of tumor mutations. *Nature methods* **10**, 1108–1115 (2013).
134. Vogelstein, B. *et al.* Cancer genome landscapes. *science* **339**, 1546–1558 (2013).
135. Cai, D., He, X., Wu, X. & Han, J. Non-negative matrix factorization on manifold. In *Data Mining, 2008. ICDM'08. Eighth IEEE International Conference on*, 63–72 (IEEE, 2008).
136. Gligorijević, V., Malod-Dognin, N. & Pržulj, N. Patient-specific data fusion for cancer stratification and personalised treatment. *Pacific Symposium on Biocomputing X*, x–y (2015).
137. Mo, Q. *et al.* Pattern discovery and cancer gene identification in integrated cancer genomic data. *Proceedings of the National Academy of Sciences* **110**, 4245–4250 (2013).
138. Napolitano, F., Zhao, Y., Moreira, V. M. *et al.* Drug repositioning: A machine-learning approach through data integration. *Journal of Cheminformatics* **5**, 30 (2013).
139. Wang, Y., Chen, S., Deng, N. & Wang, Y. Drug repositioning by kernel-based integration of molecular structure, molecular activity, and phenotype data. *PLoS ONE* **8**, e78518 (2013).
140. Zheng, X., Ding, H., Mamitsuka, H. & Zhu, S. Collaborative matrix factorization with multiple similarities for predicting drug-target interactions. In *Proceedings of the 19th ACM SIGKDD international conference on Knowledge discovery and data mining*, 1025–1033 (ACM, 2013).
141. Zhang, P., Wang, F. & Hu, J. Towards drug repositioning: a unified computational framework for integrating multiple aspects of drug similarity and disease similarity. In *AMIA Annual Symposium Proceedings*, vol. 2014, 1258 (American Medical Informatics Association, 2014).
142. Gottlieb, A., Stein, G. Y., Ruppin, E. & Sharan, R. Predict: a method for inferring novel drug indications with application to personalized medicine. *Molecular systems biology* **7**, 496 (2011).
143. Huang, Y.-F., Yeh, H.-Y. & Soo, V.-W. Inferring drug-disease associations from integration of chemical, genomic and phenotype data using network propagation. *BMC Medical Genomics* **6**, 1–14 (2013).
144. Daminelli, S., Haupt, V. J., Reimann, M. & Schroeder, M. Drug repositioning through incomplete bi-cliques in an integrated drug–target–disease network. *Integrative Biology* **4**, 778–788 (2012).
145. Jiang, W. *et al.* Identification of links between small molecules and mirnas in human cancers based on transcriptional responses. *Scientific reports* **2** (2012).
146. Chung, S. *et al.* Association of a novel long non-coding rna in 8q24 with prostate cancer susceptibility. *Cancer science* **102**, 245–252 (2011).
147. Biswas, A. *et al.* Inferring disease associations of the long non-coding rnas through non-negative matrix factorization. *Network Modeling Analysis in Health Informatics and Bioinformatics* **4** (2015).
148. Dudley, J. T., Deshpande, T. & Butte, A. J. Exploiting drug–disease relationships for computational drug repositioning. *Briefings in Bioinformatics* (2011).
149. Keiser, M. J. *et al.* Predicting new molecular targets for known drugs. *Nature* **462**, 175–181 (2009).
150. Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J. & Bork, P. Drug target identification using side-effect similarity. *Science* **321**, 263–266 (2008).
151. Van Driel, M. A., Bruggeman, J., Vriend, G., Brunner, H. G. & Leunissen, J. A. A text-mining analysis of the human phenome. *European journal of human genetics* **14**, 535–542 (2006).
152. Zhou, X., Menche, J., Barabási, A.-L. & Sharma, A. Human symptoms–disease network. *Nature communications* **5** (2014).
153. Ding, H., Takigawa, I., Mamitsuka, H. & Zhu, S. Similarity-based machine learning methods for predicting drug–target interactions: a brief review. *Briefings in Bioinformatics* (2013).
154. Yamanishi, Y., Araki, M., Gutteridge, A., Honda, W. & Kanehisa, M. Prediction of drug–target interaction networks from the integration of chemical and genomic spaces. *Bioinformatics* **24**, i232–i240 (2008).
155. Minai, R., Matsuo, Y., Onuki, H. & Hirota, H. Method for comparing the structures of protein ligand-binding sites and application for predicting protein–drug interactions. *Proteins: Structure, Function, and Bioinformatics* **72**, 367–381 (2008).

156. Chen, Y. & Zhi, D. Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule. *Proteins: Structure, Function, and Bioinformatics* **43**, 217–226 (2001).
157. Li, J. *et al.* A survey of current trends in computational drug repositioning. *Briefings in bioinformatics* **1**, 11 (2015).
158. Li, Y. & Jones, S. Drug repositioning for personalized medicine. *Genome Medicine* **4**, 27 (2012).
159. Berry, M. W., Browne, M., Langville, A. N., Pauca, V. P. & Plemmons, R. J. Algorithms and applications for approximate nonnegative matrix factorization. *Computational statistics & data analysis* **52**, 155–173 (2007).
160. Fawcett, T. An introduction to ROC analysis. *Pattern Recognition Letters* **27**, 861–874 (2006).
161. Vanunu, O., Magger, O., Ruppin, E., Shlomi, T. & Sharan, R. Associating genes and protein complexes with disease via network propagation. *PLoS Computational Biology* **6**, e1000641 (2010).
162. Wu, Z., Wang, Y. & Chen, L. Network-based drug repositioning. *Molecular BioSystems* **9**, 1268–1281 (2013).
163. Del Vescovo, V., Grasso, M., Barbareschi, M. & Denti, M. A. Micrnas as lung cancer biomarkers. *World journal of clinical oncology* **5**, 604 (2014).
164. Hayes, J., Peruzzi, P. P. & Lawler, S. Micrnas in cancer: biomarkers, functions and therapy. *Trends in molecular medicine* **20**, 460–469 (2014).
165. Wen, X., Deng, F.-M. & Wang, J. Micrnas as predictive biomarkers and therapeutic targets in prostate cancer. *American journal of clinical and experimental urology* **2**, 219 (2014).
166. Mercer, T. R., Dinger, M. E. & Mattick, J. S. Long non-coding rnas: insights into functions. *Nature Reviews Genetics* **10**, 155–159 (2009).
167. Chen, X. Predicting Incrna-disease associations and constructing Incrna functional similarity network based on the information of mirna. *Scientific Reports* **5**, 13186 (2009).
168. Carlsson, G. Topology and data. *Bulletin of the American Mathematical Society* **46**, 255–308 (2009).
169. Lum, P. *et al.* Extracting insights from the shape of complex data using topology. *Scientific reports* **3** (2013).
170. Hoens, T. R., Polikar, R. & Chawla, N. V. Learning from streaming data with concept drift and imbalance: an overview. *Progress in Artificial Intelligence* **1**, 89–101 (2012).
171. Stella, F. & Amer, Y. Continuous time bayesian network classifiers. *Journal of biomedical informatics* **45**, 1108–1119 (2012).
172. Ge, H., Walhout, A. J. & Vidal, M. Integrating ‘omic’ information: a bridge between genomics and systems biology. *Trends in Genetics* **19**, 551 – 560 (2003).
173. Mani, R., St.Onge, R. P., Hartman, J. L., Giaever, G. & Roth, F. P. Defining genetic interaction. *Proceedings of the National Academy of Sciences* **105**, 3461–3466 (2008).
174. Gligorijević, V., Janjić, V. & Pržulj, N. Integration of molecular network data reconstruct gene ontology. *Bioinformatics* **30**, i594–i600 (2014).
175. Ho, J. C., Ghosh, J. & Sun, J. Marble: high-throughput phenotyping from electronic health records via sparse nonnegative tensor factorization. In *Proceedings of the 20th ACM SIGKDD international conference on Knowledge discovery and data mining*, 115–124 (ACM, 2014).
176. Gottesman, O. *et al.* The electronic medical records and genomics (emerge) network: past, present, and future. *Genetics in Medicine* **15**, 761–771 (2013).
177. Vaudel, M. *et al.* Exploring the potential of public proteomics data. *PROTEOMICS* (2015).

Acknowledgements

Funding: This work was supported by the European Research Council (ERC) Starting Independent Researcher Grant 278212, the National Science Foundation (NSF) Cyber-Enabled Discovery and Innovation (CDI) OIA-1028394, the ARRS project J1-5454, and the Serbian Ministry of Education and Science Project III44006.